Cross-border biotech deals grow more complex as US targets China investment links

AI Summary

Cross-border biotech deals between China and the United States face increasing complexity due to heightened US scrutiny on investment and technology transfers. This regulatory environment may result in a slight slowdown of deals while geopolitical tensions strain market dynamics.

Cross-border biotech deals between China and the United States are becoming more complicated and could face a modest slowdown as Washington steps up efforts to restrict investment and technology transfers, according to industry analysts. “There will be more geopolitical scrutiny going forward. This scrutiny may lead to slightly fewer deals than without it,” said Diederik Stadig, senior healthcare economist at ING Research. Despite the growing regulatory hurdles, Stadig said the broader trend of...